Opioid formulations in development designed to curtail abuse: who is the target?

Bibliography

• Wood GB, Bache F. The dispensatory of the United States of America. Eleventh edition. Philadelphia, PA: J.B. Lippincott and Co.; 1858. p. 551-65
   Google Scholar
• Mahowald ML, Singh JA, Majeski P. Opioid use by patients in an orthopedics spine clinic. Arthritis Rheum 2005;52(1):312-21
   PubMed Web of Science ®Google Scholar
• Kalso E, Simpson KH, Slappendel R, et al. Predicting long-term response to strong opioids in patients with low back pain: findings from a randomized, controlled trial of transdermal fentanyl and morphine. BMC Med 2007;5:39
   PubMed Web of Science ®Google Scholar
• Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004;112(3):372-80
   PubMed Web of Science ®Google Scholar
• Noble M, Tregear SJ, Treadwell JR, Schoelles K. Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage 2008;35(2):214-28
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. Results from the 2007 national survey on drug use and health: national findings. NSDUH Series H-34, DHHS Publication No. SMA 08-4343. Rockville, MD: Office of Applied Studies; 2008
   Google Scholar
• Butler SF, Benoit C, Budman SH, et al. Development and validation of an opioid attractiveness scale: a novel measure of the attractiveness of opioid products to potential abusers. Harm Reduct J 2006;3:5
   PubMedGoogle Scholar
• Hays LR. A profile of OxyContin addiction. J Addict Dis 2004;23(4):1-9
   PubMed Web of Science ®Google Scholar
• McCabe SE, Cranford JA, Boyd CJ, Teter CJ. Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. Addict Behav 2007;32(3):562-75
   PubMed Web of Science ®Google Scholar
• Webster LR, Butera PG, Moran LV, et al. Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. J Pain 2006;7(12):937-46
   PubMed Web of Science ®Google Scholar
• Alpharma announces the resubmission of a New Drug Application for EMBEDA™ Capsules [press release]. Bridgewater, NJ: Alpharma, June 30, 2008. Available from: http://www.alpharma.com/pages/getpage.aspx?id=65a2358b-5aeb-4c98-b468-4232637d493b. [Accessed 23, October 2008]
   Google Scholar
• Rittenhouse PA, Usdin S. Regulation: painfully short of answers. BioCentury 2008;16(51):A1-6
   Google Scholar
• Alpharma's Phase III pivotal clinical placebo-controlled trial of its abuse-deterrent, extended release opioid demonstrates significant efficacy [press release]. Bridgewater, NJ: Alpharma; November 29, 2007. Available from: http://www.alpharma.com/pages/getpage.aspx?id=5ee99c4b-abba-4e79-9e5f-a935bfa1b6f7. [Accessed 23, October 2008]
   Google Scholar
• Jones J, Johnson F, Wagner G, et al. Evaluation of abuse potential of ALO-01, an extended-release morphine sulfate plus sequestered naltrexone formulation, among recreational opioid users. J Pain 2008;9(4):34. No. 235
   Web of Science ®Google Scholar
• Acurox™ tablets meet primary endpoint in pivotal Phase III study: Opioid with a unique composition of ingredients intended to deter common methods of prescription drug abuse [press release]. Palatine, Il, and Bristol, TN: Acura Pharmaceuticals, Inc., and King Pharmaceuticals, Inc., June 17, 2008. Available from: http://www.acurapharm.com/Press%20Releases/pr06172008.htm. [Accessed 23, October 2008]
   Google Scholar
• Acura Pharmaceuticals and King Pharmaceuticals announce positive top line results of key clinical study assessing abuse liability: Acurox™ tablets significantly disliked when excess doses are swallowed [press release]. Palatine, Il, and Bristol, TN: Acura Pharmaceuticals, Inc., and King Pharmaceuticals, Inc., October 13, 2008. Available from: http://www.acurapharm.com/Press%20Releases/pr10132008.htm. [Accessed 27, October 2008]
   Google Scholar
• Elite Pharmaceuticals, Inc. reports opioid abuse-resistant products gaining momentum. Elite provides update on company's progress and projected milestones [press release]. Northvale, NJ: Elite Pharmaceuticals, Inc., March 31, 2008. Available from: http://www.elitepharma.com/investor_relations.asp?goto=296. [Accessed 23, October 2008]
   Google Scholar
• Webster LR. PTI-821: sustained-release oxycodone using gel-cap technology. Expert Opin Invest Drugs 2007;16(3):359-66
   PubMed Web of Science ®Google Scholar
• Gilderman L, Butera P, Gilmore D, et al. Remoxy™: a new opioid drug with effective analgesia and abuse-resistance. Program and abstracts of the 25th Annual Scientific Meeting of the American Pain Society, San Antonio, USA (3 – 6 May 2006):755 (Poster)
   Google Scholar
• Friedmann N, Butera P, Klutzaritz D, et al. Abuse-resistant, long-acting oxycodone treats chronic pain in a large Phase III study. International Association for the Study of Pain. 2008. Glascow, Scotland
   Google Scholar
• Wallace M, Skowronski R, Khanna S, et al. Efficacy and safety evaluation of once-daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127). Curr Med Res Opin 2007;23(5):981-89
   PubMed Web of Science ®Google Scholar
• Neuromed initiates pivotal Phase 3 clinical trial of NMED-1077 for chronic pain [press release]. Conshohocken, PA and Vancouver, BC: Neuromed Pharmaceuticals, November 1, 2007. Available from: http://www.neuromed.com/news/pressr.php?nr=4&txt=&pyear=2007. [Accessed 23, October 2008]
   Google Scholar
• Sabatowski R, Giesecke T. Pharmacotherapy of chronic, non-tumor related pain. Efficacy, tolerability and patient benefit of an oral osmotic system with hydromorphone. MMW Fortschr Med 2007;149(Suppl 3):119-24
   PubMedGoogle Scholar
• Sathyan G, Sivakumar K, Thipphawong J. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence of alcohol. Curr Med Res Opin 2008;24(1):297-305
   PubMed Web of Science ®Google Scholar
• IntelliPharmaCeutics announces successful completion of a pilot clinical trial for its abuse and alcohol resistant sustained release oxycodone [press release]. Toronto: IntelliPharmaCeutics Corp., March 27, 2008. Available from: http://newsblaze.com/story/2008032710330300004.pnw/topstory.html. [Accessed 23, October 2008]
   Google Scholar
• Collegium Pharmaceutical Inc., announces the filing of IND for abuse deterrent sustained release opioid product [press release]. Cumberland, RI: Collegium Pharmaceutical, Inc., June 15, 2007. Available from: http://www.acurapharm.com/Press%20Releases/pr10132008.htm. [Accessed 27, October 2008]
   Google Scholar
• TheraQuest receives FDA fast track designation for Tramadol ER in painful HIV-associated neuropathy [press release]. Blue Bell, PA: TheraQuest Biosciences, LLC, April 18, 2006
   Google Scholar
• TheraQuest's abuse deterrent tramadol ER IND for neuropathic pain accepted by FDA. Blue Bell, PA: TheraQuest Biosciences, LLC, February 6, 2006. Available from: http://www.pipelinereview.com/content/view/638/105/. [Accessed 27, October 2008]
   Google Scholar
• Pedersen AV. Erosion-based drug delivery. Manufacturing Chemist, November 2006. Available from: http://www.egalet.com/ press_releases.aspx. [Accessed 19, November 2008]
   Google Scholar
• Purdue Pharma L.P. Meeting Background Material. Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee (ALSDAC) and Drug Safety and Risk Management Advisory Committee (DSaRM). May 5, 2008. Available from: http://www.fda.gov/OHRMS/DOCKETS/ac/08/briefing/2008-4356b1-02-Purdue.pdf [Last accessed online 8 January 2009].
   Google Scholar
• Wright C 4th, Kramer ED, Zalman MA, et al. Risk identification, risk assessment, and risk management of abusable drug formulations. Drug Alcohol Depend 2006;83(Suppl 1):S68-76
   PubMedGoogle Scholar
• Comer SD, Sullivan MA, Whittington RA, et al. Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. Neuropsychopharmacology 2008;33(5):1179-91
   PubMed Web of Science ®Google Scholar
• Friedmann N, de Kater AW, Butera PG, et al. RemoxyTM: a novel drug candidate, deters oxycodone abuse in humans. Presented at 21st annual meeting of the American Academy of Pain Medicine, 2005
   Google Scholar